About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Docs on Twitter


Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Astellas to Acquire Agensys,Inc. | Main | Exiqon to Acquire Oncotech »

November 28, 2007

InterMune Buys out License Agreement for Pirfenidone

    By Christopher P. Singer --

Intermunelogo In a November 26, 2007 press release, InterMune Inc. announced that it will purchase patent rights to pirfenidone from Marnac, Inc. and KDL GmbH.  This acquisition includes patent rights that InterMune had been licensing from Marnac and KDL as well as other international IP rights relating to pirfenidone that were not part of the prior existing license agreement.  Those additional IP rights include patents that relate to TNF-alpha based activities of pirfenidone.  Currently, pirfenidone is under two large phase 3 clinical trials to determine the safety and efficacy in the treatment of idiopathic pulmonary fibrosis (IPF).  Both the FDA and European Medicines Evaluation Agency (EMEA) have granted pirfenidone orphan drug status for treatment of IPF.

Pirfenidone The buyout and purchase does not affect rights to pirfenidone (at left) in Japan, Korea, and Taiwan, which rights remain licensed by Marnac to Shionogi & Co. Ltd.  The terms of the purchase include upfront payments from InterMune totaling $13.5 million, and could include an additional $53.5 million in payments if pirfenidone achieves positive Phase 3 data and is registered in the U.S. and Europe.  All of InterMune's milestone and royalty payments under the prior license agreement are extinguished by this purchase.

Posted at 11:06 PM in Licensing |

Comments

The comments to this entry are closed.

March 2023

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

Categories

Archives

More...